NEWS
最新消息
2020-China's Biomedicine Ushers in the Upsurge of Listing
发布时间：
2020-11-20 13:53
Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies.
Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.
According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:
| S/N |
Company name |
Stock Exchange |
Capital Raised |
Business area |
| 1 |
Akeso,Inc |
HKEx |
Over $300 million |
Tumour、Autoimmune disease |
| 2 |
Innocare |
HKEx |
About HK$2.093 billion |
Cancer、Autoimmune disease |
| 3 |
Kintor Pharmaceutical Limited |
HKEx |
About $240 million |
Prostate Cancer、Breast Cancer Liver cancer、Baldness |
| 4 |
Zai Lab Limited |
HKEx |
HK$5.73 billion |
Tumour、Autoimmune disease |
| 5 |
Immunotech Biopharm Ltd |
HKEx |
HK$1.0241 billion |
T-Cell Immunotherapy |
| 6 |
Ocumension Therapeutics |
HKEx |
HK$1.553 billion |
Ophthalmology |
| 7 |
Hepalink |
HKEx |
HK$3.8 billion |
Heparin、Tumour |
| 8 |
Jhbp (Cy) Holdings Limited |
HKEx |
----- |
Tumour、Autoimmune disease |
| 9 |
Everest Medicines Limited |
HKEx |
----- |
Tumour、Autoimmune disease Cardiorenal diseases Infectious disease |
| 10 |
Simcere Pharmaceutical Group Limited |
HKEx |
----- |
Tumour、Central nervous system diseases、Autoimmune disease |
| 11 |
Jw (Cayman) Therapeutics Co. Ltd |
HKEx |
----- |
CAR-T |
| 12 |
Remegen Co. Ltd. |
HKEx |
----- |
Autoimmune disease、Tumour Ophthalmology |
| 13 |
Antengene Corporation Limited |
HKEx |
----- |
Tumour |
| 14 |
Zelgen |
STAR Market |
About ¥2.026 billion |
Tumour、Hematopathy |
| 15 |
Bio-Thera Solutions, Ltd |
STAR Market |
About ¥2.0 billion |
Tumour、Autoimmune disease |
| 16 |
Sinocelltech Grou Limited |
STAR Market |
About ¥1.282 billion |
Monoclonal Antibody Recombination Protein、Vaccine |
| 17 |
HitGen Inc. |
STAR Market |
About ¥830 million |
The lead drug |
| 18 |
Cansino Biologics Inc. |
STAR Market |
About ¥5.2 billion |
Vaccine |
| 19 |
Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd. |
STAR Market |
¥3.183 billion |
Antibody |
| 20 |
Jiangsu Aidea Pharmaceutical Co.,ltd |
STAR Market |
¥839.4 million |
Antidote、Tumour |
| 21 |
Junshi BiosciencesCo., Ltd. |
STAR Market |
About ¥2.7 billion |
Tumour、Chronic disease Autoimmune disease |
| 22 |
Easton BioPharmaceuticals Co.,Ltd |
STAR Market |
¥1.335 billion |
Combination of generic drug development |
| 23 |
Frontier Biotechnologies Inc |
STAR Market |
¥1.845 billion |
AIDS antiviral treatment. Pain therapy |
In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market
the,hkex,star,market,billion,disease,tumour,yen,autoimmune
